These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38771994)

  • 81. Effect of prior cancer on survival of hepatocellular carcinoma: implications for clinical trial eligibility criteria.
    Sun X; Li L; Xu L; Zhou Z; Chen J; Wang J; Zhang Y; Hu D; Chen M
    BMC Cancer; 2021 Feb; 21(1):147. PubMed ID: 33563246
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies.
    Srikanthan A; Vera-Badillo F; Ethier J; Goldstein R; Templeton AJ; Ocana A; Seruga B; Amir E
    Cancer Treat Rev; 2016 Feb; 43():67-73. PubMed ID: 26827694
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity.
    Garcia S; Bisen A; Yan J; Xie XJ; Ramalingam S; Schiller JH; Johnson DH; Gerber DE
    J Thorac Oncol; 2017 Oct; 12(10):1489-1495. PubMed ID: 28802905
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Patient and physician factors associated with participation in cervical and uterine cancer trials: an NRG/GOG247 study.
    Brooks SE; Carter RL; Plaxe SC; Basen-Engquist KM; Rodriguez M; Kauderer J; Walker JL; Myers TK; Drake JG; Havrilesky LJ; Van Le L; Landrum LM; Brown CL
    Gynecol Oncol; 2015 Jul; 138(1):101-8. PubMed ID: 25937529
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Eligibility for Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma: A Population-based Study.
    Tsang ES; Davies JM; Loree JM; Lim HJ; Renouf DJ; Gill S
    Am J Clin Oncol; 2020 Nov; 43(11):788-791. PubMed ID: 32868523
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Racial and ethnic disparities in meeting Part D MTM eligibility criteria among the non-Medicare population.
    Wang J; Brown LM; Hong SH
    J Am Pharm Assoc (2003); 2012; 52(5):e87-96. PubMed ID: 23023863
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Does enrollment in cancer trials improve survival?
    Chow CJ; Habermann EB; Abraham A; Zhu Y; Vickers SM; Rothenberger DA; Al-Refaie WB
    J Am Coll Surg; 2013 Apr; 216(4):774-80; discussion 780-1. PubMed ID: 23415510
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016.
    Chen X; Schaufelberger M; Fu M
    J Cardiovasc Med (Hagerstown); 2020 Jan; 21(1):6-12. PubMed ID: 31789711
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Patient Eligibility for Randomized Controlled Trials in Critical Care Medicine: An International Two-Center Observational Study.
    Ivie RM; Vail EA; Wunsch H; Goldklang MP; Fowler R; Moitra VK
    Crit Care Med; 2017 Feb; 45(2):216-224. PubMed ID: 27779514
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Leveraging electronic health record data for clinical trial planning by assessing eligibility criteria's impact on patient count and safety.
    Rogers JR; Pavisic J; Ta CN; Liu C; Soroush A; Kuen Cheung Y; Hripcsak G; Weng C
    J Biomed Inform; 2022 Mar; 127():104032. PubMed ID: 35189334
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies.
    Aldrighetti CM; Niemierko A; Van Allen E; Willers H; Kamran SC
    JAMA Netw Open; 2021 Nov; 4(11):e2133205. PubMed ID: 34748007
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Comparison of Racial, Ethnic, and Geographic Location Diversity of Participants Enrolled in Clinic-Based vs 2 Remote COVID-19 Clinical Trials.
    Stewart J; Krows ML; Schaafsma TT; Heller KB; Brown ER; Boonyaratanakornkit J; Brown CE; Leingang H; Liou C; Bershteyn A; Schwartz MD; Agrawal V; Friedman-Klabanoff D; Eustace S; Stankiewicz Karita HC; Paasche-Orlow MK; Kissinger P; Hosek SG; Chu HY; Celum C; Baeten JM; Wald A; Johnston C; Barnabas RV
    JAMA Netw Open; 2022 Feb; 5(2):e2148325. PubMed ID: 35157053
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Examining Differences in Opportunity and Eligibility for Cancer Clinical Trial Participation Based on Sociodemographic and Disease Characteristics.
    Rearden J; Hanlon AL; Ulrich C; Brooks-Carthon M; Sommers M
    Oncol Nurs Forum; 2016 Jan; 43(1):57-66. PubMed ID: 26679445
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Clinical trial representativeness and treatment intensity in a real-world sample of women with early stage breast cancer.
    Rocque GB; Caston NE; Franks JA; Williams CP; Aswani MS; Azuero A; Gidwani R
    Breast Cancer Res Treat; 2021 Dec; 190(3):531-540. PubMed ID: 34585334
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Automatic trial eligibility surveillance based on unstructured clinical data.
    Meystre SM; Heider PM; Kim Y; Aruch DB; Britten CD
    Int J Med Inform; 2019 Sep; 129():13-19. PubMed ID: 31445247
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Patterns of National Cancer Institute-Sponsored Clinical Trial Enrollment in Black Adolescents and Young Adults.
    Roth M; Beauchemin M; Kahn JM; Bleyer A
    Cancer Med; 2021 Nov; 10(21):7620-7628. PubMed ID: 34592782
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Evaluation of Racial, Ethnic, and Socioeconomic Associations With Treatment and Survival in Uveal Melanoma, 2004-2014.
    Rajeshuni N; Zubair T; Ludwig CA; Moshfeghi DM; Mruthyunjaya P
    JAMA Ophthalmol; 2020 Aug; 138(8):876-884. PubMed ID: 32614376
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials.
    Kanapuru B; Fernandes LL; Baines A; Ershler R; Bhatnagar V; Pulte E; Gwise T; Theoret MR; Pazdur R; Fashoyin-Aje L; Gormley N
    Blood; 2023 Jul; 142(3):235-243. PubMed ID: 37140031
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Participation in pediatric oncology research protocols: Racial/ethnic, language and age-based disparities.
    Aristizabal P; Singer J; Cooper R; Wells KJ; Nodora J; Milburn M; Gahagan S; Schiff DE; Martinez ME
    Pediatr Blood Cancer; 2015 Aug; 62(8):1337-44. PubMed ID: 25755225
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.